Menu
Enrolling by invitation NCT07654634

Precision Antithrombotic Therapy

— Observational Non-valvular Atrial Fibrillation (NVAF) Venous Thromboembolism (VTE) MI(Myocardial Infarction) Ischemic Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Not applicable- observational study.
Who it may be relevant to
Registry conditions: Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke. Basic parameters: from 8 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Multicenter Cohort Study on Precision Antithrombotic Therapy

Overview

The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level evidence for therapeutic drug monitoring (TDM) and personalized dosing.The main questions it aims to answer are: * What are the optimal preventive and therapeutic concentration ranges for different NOACs (rivaroxaban, apixaban, dabigatran, edoxaban) and antiplatelet drugs (aspirin, indobufen)? * What are the key factors influencing the blood drug concentrations of NOACs and antiplatelet drugs (such as liver and kidney function, age, weight, concomitant medications)? * How can we establish a model to predict blood drug concentrations of NOACs and antiplatelet drugs and their related clinical events? Participants will receive routine clinical care. During treatment, blood samples will be regularly collected to measure patients' blood drug concentrations (Ctrough and Cmax), and clinical responses and adverse events will be recorded.

Interventions

  • Other Not applicable- observational study
    not have

Primary outcome measures

  • Efficacy Endpoint: Composite thrombotic events (ischemic stroke, systemic embolism, myocardial infarction, deep vein thrombosis, pulmonary embolism) [Time frame: At the 1st month, 3rd month and 6th month after enrollment]
  • Safety Endpoint: Bleeding events (major bleeding and clinically relevant non-major bleeding) [Time frame: At the 1st month, 3rd month and 6th month after enrollment]

Eligibility criteria

Inclusion criteria

  • Age ≥ 8 years old;
  • Diagnosed with one of the following diseases and in need of long - term anticoagulant therapy: non - valvular atrial fibrillation (CHA₂DS₂ - VA score ≥ 1); venous thromboembolism (deep vein thrombosis or pulmonary embolism); having other indications for using NOACs to prevent and treat thrombotic diseases;
  • Currently receiving NOAC treatment (rivaroxaban, apixaban, dabigatran etexilate, edoxaban);
  • Willing and able to comply with the requirements of the research protocol and the follow - up plan;
  • Signed the informed consent form.
  • Age ≥ 18 years old;
  • Assessed as patients at high risk of bleeding within 72 hours after the onset of symptoms;
  • Receiving indobufen treatment for the first time after admission;
  • Willing and able to comply with the requirements of the research protocol and the follow - up plan;
  • Signed the informed consent form.

Exclusion criteria

  • Having contraindications to the use of NOACs or being allergic to NOACs;
  • Having been enrolled in other clinical trials.
  • Being allergic to or having contraindications to indobufen;
  • Needing to change antithrombotic drugs or combine with other antiplatelet/anticoagulant therapies (such as clopidogrel, ticagrelor, warfarin, heparin, etc.) during the study;
  • Cardiogenic stroke or stroke induced by angioplasty/vascular surgery;
  • Having a history of aneurysm (intracranial or peripheral);
  • Severe abnormal liver and kidney functions;
  • Pregnant, lactating women or women of childbearing age who are unwilling to take effective contraceptive measures;
  • Life expectancy < 1 year;
  • Mental or emotional disorders preventing cooperation with follow - up;
  • Participating in other clinical trials within 30 days before enrollment;
  • Unable to complete blood concentration detection (such as difficulty in establishing venous access).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Xiangya Third Hospital of Central South University — Changsha

Identifiers

NCT: NCT07654634 · fast26359

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗